NCL ICB has commissioned a programme of work from January 2025 to March 2026 to review patients with chronic kidney disease (CKD) stages G3a-G5 who could be prescribed an SGLT2 inhibitor, but who are not currently prescribed the medication. This intervention will be beneficial to the patient’s health and self-management of their condition. SGLT-2i used appropriately in CKD can impact significantly on both the rates of heart attacks and strokes in these patients, but also to reduce the number who reach end stage kidney disease and renal replacement therapy. 

To support this work, please join a one-hour interactive session with experts from the NCL CKD Integrated Service. 

Please note: you will need Q&A access, and to respond to polls. To do this, you need to:
1.    Join the meeting from the MS Teams app and not through the browser
2.    Have access to click on links or scan a QR code.

Event dates will be released throughout the year, until February 2026, with meeting links provided within two months of the event. Booking is by registration only, and live attendance is required for certification. 

Events are listed on the Events Calendar, go to the month and search 'CKD'.